Vertex Pharmaceuticals Incorporated (VRTX) Stock Overview
Explore Vertex Pharmaceuticals Incorporated’s financial performance, market position, analyst ratings, and future outlook.
Vertex Pharmaceuticals Incorporated (VRTX)
Key Financials
Key Financials
Market Cap
133.9B
P/E Ratio
30.53
EPS (TTM)
$19.03
ROE
0.23%
VRTX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Vertex Pharmaceuticals Incorporated's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of VRTX on the NASDAQ shows an RSI of 53.90, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $523.41 for the NASDAQ listing.
Key metrics behind Vertex Pharmaceuticals Incorporated's NASDAQ-traded stock include a P/E ratio of 30.53 and a market capitalization of 133.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of VRTX on the NASDAQ.